Nanocarriers for gene delivery to the cardiovascular system

Shi, Ling-Xin; Liu, Xiu-Ran; Zhou, Ling-Yue; Zhu, Zi-Qi; Yuan, Qiong; Zou, Tao

doi:10.1039/d3bm01275a

Cited by 6 publications

(2 citation statements)

References 162 publications

(198 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…INPs are synthesized from inorganic particles and biodegradable polycations [105], including metals, metal oxides, carbon materials, and magnetic nanoparticles such as superparamagnetic iron oxide NPs [106]. Their inherent biocompatibility, stability, resistance to microbial degradation, and efficient delivery contribute to their clinical significance [107].…”

Section: Inorganic Nps (Inps)mentioning

confidence: 99%

Nanomaterials-assisted gene editing and synthetic biology for optimizing the treatment of pulmonary diseases

Lei,

Pan,

Shou

et al. 2024

J Nanobiotechnol

View full text Add to dashboard Cite

The use of nanomaterials in gene editing and synthetic biology has emerged as a pivotal strategy in the pursuit of refined treatment methodologies for pulmonary disorders. This review discusses the utilization of nanomaterial-assisted gene editing tools and synthetic biology techniques to promote the development of more precise and efficient treatments for pulmonary diseases. First, we briefly outline the characterization of the respiratory system and succinctly describe the principal applications of diverse nanomaterials in lung ailment treatment. Second, we elaborate on gene-editing tools, their configurations, and assorted delivery methods, while delving into the present state of nanomaterial-facilitated gene-editing interventions for a spectrum of pulmonary diseases. Subsequently, we briefly expound on synthetic biology and its deployment in biomedicine, focusing on research advances in the diagnosis and treatment of pulmonary conditions against the backdrop of the coronavirus disease 2019 pandemic. Finally, we summarize the extant lacunae in current research and delineate prospects for advancement in this domain. This holistic approach augments the development of pioneering solutions in lung disease treatment, thereby endowing patients with more efficacious and personalized therapeutic alternatives.

show abstract

Section: Inorganic Nps (Inps)mentioning

confidence: 99%

Nanomaterials-assisted gene editing and synthetic biology for optimizing the treatment of pulmonary diseases

Lei,

Pan,

Shou

et al. 2024

J Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…6 To achieve this goal, researchers have been exploring more efficient and safe genes and gene vectors. 7,8 The group's previous study found that the human C2H2-type zinc finger protein gene ZNF580 is involved in the transcriptional regulation of angiogenesis. 9 In human umbilical vein endothelial cell (HUVEC) lines, overexpression of the ZNF580 gene promotes the expression of MMP-2 and VEGF and enhances the migratory and proliferative activities of HUVECs.…”

Section: Introductionmentioning

confidence: 99%

CAG peptide functionalized graphene quantum dots-cationic polymer composite gene carriers

Duo,

Xu,

et al. 2024

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

Chenodeoxycholic Acid‐Modified Polyethyleneimine Nano‐Composites Deliver Low‐Density Lipoprotein Receptor Genes for Lipid‐Lowering Therapy by Targeting the Liver

Guo,

Xu,

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

Lipid‐lowering drugs, especially statins, are extensively utilized in clinical settings for the prevention of hyperlipidemia. Nevertheless, prolonged usage of current lipid‐lowering medications is associated with significant adverse reactions. Therefore, it is imperative to develop novel therapeutic agents for lipid‐lowering therapy. In this study, a chenodeoxycholic acid and lactobionic acid double‐modified polyethyleneimine (PDL) nanocomposite as a gene delivery vehicle for lipid‐lowering therapy by targeting the liver, are synthesized. Results from the in vitro experiments demonstrate that PDL exhibits superior transfection efficiency compared to polyethyleneimine in alpha mouse liver 12 (AML12) cells and effectively carries plasmids. Moreover, PDL can be internalized by AML12 cells and rapidly escape lysosomal entrapment. Intravenous administration of cyanine5.5 (Cy5.5)‐conjugated PDL nanocomposites reveals their preferential accumulation in the liver compared to polyethyleneimine counterparts. Systemic delivery of low‐density lipoprotein receptor plasmid‐loaded PDL nanocomposites into mice leads to reduced levels of low‐density lipoprotein cholesterol (LDL‐C) and triglycerides (TC) in the bloodstream without any observed adverse effects on mouse health or well‐being. Collectively, these findings suggest that low‐density lipoprotein receptor plasmid‐loaded PDL nanocomposites hold promise as potential therapeutics for lipid‐lowering therapy.

show abstract

Nanocarriers for gene delivery to the cardiovascular system

Abstract: Cardiovascular diseases have posed a great threat to human health. Fortunately, gene therapy holds great promise in the fight against cardiovascular disease (CVD). In gene therapy, it is necessary to...

Cited by 6 publications

References 162 publications

Nanomaterials-assisted gene editing and synthetic biology for optimizing the treatment of pulmonary diseases

Nanomaterials-assisted gene editing and synthetic biology for optimizing the treatment of pulmonary diseases

CAG peptide functionalized graphene quantum dots-cationic polymer composite gene carriers

Chenodeoxycholic Acid‐Modified Polyethyleneimine Nano‐Composites Deliver Low‐Density Lipoprotein Receptor Genes for Lipid‐Lowering Therapy by Targeting the Liver

Contact Info

Product

Resources

About